Frederic Desdouits
Chief Executive Officer OranoMed
Frédéric Desdouits took the position of CEO of Orano Med in April 2026, having previously served as a member of its Governance Board since 2022. Prior to joining Orano Med, he was CEO of TreeFrog Therapeutics, a French biotech specializing in stem cell-based therapies. He also led pharmaceutical activities at Seqens, a global specialty ingredients manufacturer, and oversaw business development and U.S. pharmaceutical operations at Pierre Fabre. Earlier, he co-founded Bionest Partners and headed Exane BNP Paribas’ European pharma and biotech analysis team, beginning his career in pharmaceutical research. Frédéric is also Vice President of France Biotech. He graduated from École Polytechnique, holds a PhD in neurosciences from Paris VI Sorbonne, and completed postdoctoral research at Rockefeller University.
Seminars
- Presenting Phase II clinical data evaluating the safety, efficacy and therapeutic potential of Pb-212-based targeted alpha therapies
- Exploring how clinical findings are shaping patient selection, dosing strategies and future development decisions
- Examining the key translational and operational learnings generated throughout Phase II development
